Literature DB >> 9051842

Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy.

P E Rubsamen1, S W Cousins.   

Abstract

OBJECTIVE: To test the therapeutic effect of periocular corticosteroid injection on outcome, vitreous cellular infiltrate, and vitreous soluble growth-stimulating activity in an experimental model of tractional retinal detachment resulting from proliferative vitreoretinopathy.
METHODS: An experimental model of proliferative vitreoretinopathy was induced in rabbits, which then were selected randomly to receive either periocular methylprednisolone acetate injection treatment or a placebo injection (control). Animals were examined and monitored to determine the degree of retinal detachment and proliferative vitreoretinopathy at weekly intervals for 4 weeks. Vitreous specimens were obtained each week and analyzed for cell number by flow cytometry and for soluble growth-stimulating activity using a bioassay.
RESULTS: Eighty-six percent (12 of 14) of the rabbits receiving periocular steroid injection had retinas that remained attached, whereas only 13 percent (2 of 15) of control animals had retinas that remained attached. Periocular steroid injections were associated with a significant decrease in the vitreous soluble proliferation stimulating activity at all times during experimental proliferative vitreoretinopathy. Vitreous cellular infiltration also was reduced significantly in steroid-treated animals compared with that of control animals. Finally, the magnitude of the soluble growth-stimulating activity at day 7, before onset of proliferative vitreoretinopathy, was highly predictive of outcome 3 weeks later.
CONCLUSION: Periocular steroids decreased the incidence of complicated retinal detachment caused by proliferative vitreoretinopathy in this rabbit model. Decreased vitreous cellular infiltrate and soluble proliferation stimulating activity within the vitreous microenvironment also was observed to be associated with successful outcome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9051842     DOI: 10.1097/00006982-199701000-00009

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  14 in total

1.  Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy.

Authors:  José A Roca; Analí Yon-Mendoza; Nathaly Huamán; Lihteh Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-26       Impact factor: 3.117

2.  The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment.

Authors:  Yong Wei; RongLe Zhou; Xiaobo Wang; Xiuju Chen; Hao Chen
Journal:  Eye (Lond)       Date:  2019-04-02       Impact factor: 3.775

3.  Proliferative vitreoretinopathy and antivascular endothelial growth factor treatment.

Authors:  K Ghasemi Falavarjani; M Modarres
Journal:  Eye (Lond)       Date:  2014-08-08       Impact factor: 3.775

4.  Comparison of the effects of intravitreal bevacizumab and dexamethasone in experimental posterior penetrating eye injury.

Authors:  Ayse Oner; Nisa Kahraman; Saim Ozdamar; Esra Balcioglu
Journal:  Int J Ophthalmol       Date:  2018-04-18       Impact factor: 1.779

5.  Surgical outcomes of preoperative steroid for rhegmatogenous retinal detachment with associated choroidal detachment.

Authors:  A Denwattana; S Prakhunhungsit; S Thoongsuwan; N Rodanant; N Phasukkijwatana
Journal:  Eye (Lond)       Date:  2017-12-08       Impact factor: 3.775

6.  Posterior subtenon triamcinolone acetonide in gas-filled eyes as an adjunctive treatment for complicated proliferative diabetic retinopathy.

Authors:  Yongeun Lee; Seungbum Kang; Young-Hoon Park
Journal:  Korean J Ophthalmol       Date:  2013-01-09

7.  Postoperative Macular Proliferative Vitreoretinopathy: A Case Series and Literature Review.

Authors:  Samer Khateb; Hamzah Aweidah; Michael Halpert; Tareq Jaouni
Journal:  Case Rep Ophthalmol       Date:  2021-05-27

8.  A pilot study of intraocular use of intensive anti-inflammatory; triamcinolone acetonide to prevent proliferative vitreoretinopathy in eyes undergoing vitreoretinal surgery for open globe trauma; the Adjuncts in Ocular Trauma (AOT) Trial: study protocol for a randomised controlled trial.

Authors:  Philip J Banerjee; Malcolm G Woodcock; Catey Bunce; Robert Scott; David G Charteris
Journal:  Trials       Date:  2013-02-13       Impact factor: 2.279

9.  Proliferative vitreoretinopathy: current and emerging treatments.

Authors:  Ama Sadaka; Gian Paolo Giuliari
Journal:  Clin Ophthalmol       Date:  2012-08-14

10.  Ozurdex (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial.

Authors:  Philip J Banerjee; Catey Bunce; David G Charteris
Journal:  Trials       Date:  2013-10-28       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.